Characterizing Benefit in Responders in the CheckMate 901 Trial

At the AUA 2024 Annual Meeting, David Ambinder, MD, of New York Medical College/Westchester Medical Center, and Guru Sonpavde, MD, of AdventHealth Cancer Institute, provide a comprehensive update of the phase 3 CheckMate 901 trial, a randomized trial of nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone in patients with previously untreated, unresectable or metastatic urothelial carcinoma.

The latest analysis characterizes treatment benefit in responders from the trial.